These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18311658)

  • 1. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity.
    Smolewski P
    IDrugs; 2008 Mar; 11(3):204-14. PubMed ID: 18311658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration.
    Lopez RA; Goodman AB; Rhodes M; Blomberg JA; Heller J
    Anticancer Drugs; 2007 Sep; 18(8):933-9. PubMed ID: 17667599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers.
    Khanna N; Dalby R; Connor A; Church A; Stern J; Frazer N
    Sex Transm Dis; 2008 Jun; 35(6):577-82. PubMed ID: 18418294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
    Ho SS; Go ML
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6127-33. PubMed ID: 24080463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma.
    Sun Y; Giacalone NJ; Lu B
    J Thorac Oncol; 2011 Jan; 6(1):8-14. PubMed ID: 21107289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzastaurin.
    Ma S; Rosen ST
    Curr Opin Oncol; 2007 Nov; 19(6):590-5. PubMed ID: 17906457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
    Mills DA; Fekrazad HM; Verschraegen CF
    Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
    Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
    Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
    Atadja P
    Cancer Lett; 2009 Aug; 280(2):233-41. PubMed ID: 19344997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer.
    Ito E; Yip KW; Katz D; Fonseca SB; Hedley DW; Chow S; Xu GW; Wood TE; Bastianutto C; Schimmer AD; Kelley SO; Liu FF
    Mol Pharmacol; 2009 Nov; 76(5):969-83. PubMed ID: 19654225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of nordihydroguaiaretic acid derivatives and their bioactivities on S. pombe and K562 cell lines.
    Li X; Jiang JH; Chen Q; Xiao SX; Li CH; Gu HW; Zhang H; Hu JL; Yao FH; Li QG
    Eur J Med Chem; 2013 Apr; 62():605-13. PubMed ID: 23434529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications.
    Medici V; Sturniolo GC
    IDrugs; 2008 Aug; 11(8):592-606. PubMed ID: 18683094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
    Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
    Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.